Dumenil D, Droz D, Droz J P, Frindel E
Cancer Chemother Pharmacol. 1982;8(3):267-70. doi: 10.1007/BF00254048.
cis-Platinum is a relatively new active anticancer drug. In the study described in this paper, its toxicity was tested in the hematopoietic and renal systems of mice after six injections of 3 mg per kg body weight at 10-day intervals. Acute hematopoietic toxicity was studied by determining the survival of pluripotent (CFU-S) and granulo-macrophagic unipotent (GM-CFC) stem cells. The number of nucleated cells in the bone marrow and in the spleen and the number of granulocytes in the blood were determined. Renal toxicity was studied by histological examination of kidneys from treated mice compared with control animals. The number of stem cells in the bone marrow and in the spleen decreased during the treatment. One year after treatment, the autorepopulating ability of CFU-S was still diminished in spite of normal numbers of these cells. No renal damage could be demonstrated by light microscopy when the protocol described was used.